Palisade Bio (PALI) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Palisade Bio (PALI) over the past year, gaining 23.1% versus a loss of 11.9%. Over five years, SABS leads with a -97.1% price change compared with -99.9% for PALI. SAB Biotherapeutics is the larger company by market cap ($262.0 million vs $257.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PALI | SABS |
|---|---|---|
| Share price | $1.48 | $2.88 |
| Market cap | $257.92M | $262.04M |
| 1-day change | -0.67% | -1.71% |
| YTD return | -37.02% | -22.99% |
| 1-year return | -11.90% | +23.08% |
| 5-year return | -99.93% | -97.15% |
| P/E ratio (TTM) | 2.47 | — |
| EPS (TTM) | $0.60 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.86 | $5.15 |
| 52-week low | $1.32 | $2.10 |
| Distance from 52-week high | -48.25% | -44.08% |
| Average volume | 2.64M | 495.86K |
| Shares outstanding | 174.27M | 90.99M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed PALI by 35.0 percentage points over the past year.
PALI vs SABS FAQ
Which is bigger, Palisade Bio or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $262.04M compared with $257.92M for Palisade Bio (PALI).
Which stock has performed better over the past year, PALI or SABS?
SABS returned +23.08% over the past 12 months, compared with -11.90% for PALI (price return, excluding dividends). Past performance does not predict future results.
Are Palisade Bio and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.